カテゴリー： 世界, 医療/バイオ, Grand View Research

世界のがん支持療法治療薬市場2023-2030：治療薬クラス別（G-CSF、ESA、制吐薬、ビスホスホネート、オピオイド、NSAID）、地域別（北米、ヨーロッパ）

【英語タイトル】Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, ESAs, Antiemetics, Bisphosphonates, Opioids, NSAIDs), By Region (North America, Europe), And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23JUN004）・商品コード：GRV23JUN004
・発行会社（調査会社）：Grand View Research
・発行日：2023年5月16日
・ページ数：120
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Grand View Research社の市場調査書によると、世界のがん支持療法治療薬市場規模が、予測期間中（2023年～2030年）に年平均-1.26％減少し、2030年までに121.7億ドルへ達すると見込まれています。本調査書では、がん支持療法治療薬の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、治療薬クラス別（G-CSF（顆粒球コロニー刺激因子）、ESA（赤血球造血刺激因子）、制吐薬、ビスホスホネート、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋中南米、中東・アフリカ）分析、競争状況などについて調査・分析し、まとめています。なお、こちらに掲載されている企業情報には、Amgen, Inc.、Merck & Co., Inc.、Johnson & Johnson Services, Inc.、Heron Therapeutics, Inc.、Novartis Ag、Gsk Plc、F. Hoffmann-La Roche Ltd.、Helsinn Healthcare Saなどが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・世界がん支持療法治療薬の市場規模：治療薬クラス別
- G-CSF（顆粒球コロニー刺激因子）の市場規模
- ESA（赤血球造血刺激因子）の市場規模
- 制吐薬の市場規模
- ビスホスホネートの市場規模
- その他がん支持療法治療薬の市場規模
・世界がん支持療法治療薬の市場規模：地域別
- 北米のがん支持療法治療薬市場規模
- ヨーロッパのがん支持療法治療薬市場規模
- アジア太平洋のがん支持療法治療薬市場規模
- 中南米のがん支持療法治療薬市場規模
- 中東・アフリカのがん支持療法治療薬市場規模
・競争状況

がん支持療法治療薬市場の成長と動向

Grand View Research社の最新レポートによると、がん支持療法治療薬の世界市場規模は2030年までに121億7000万米ドルに達すると予測されています。2023年から2030年にかけての年平均成長率（CAGR）は-1.26%と予測されています。この減少は、バイオシミラーの発売や、従来の化学療法薬よりも副作用の少ない癌の標的治療薬の承認・普及などの要因によるものです。がん罹患率の増加、発展途上地域における化学療法などの伝統的治療法の採用と依存度の高さ、高齢者人口の増加は、市場成長を促進する顕著な要因の一部です。Globocan社によると、今後20年間に新たに発生するがん患者数は2,840万人に達し、2020年からは47%増加すると予想されています。

また、アジアやアフリカ諸国などの発展途上地域では、可処分所得水準が低く、適切な償還シナリオがないため、他の高額な標的療法に比べて化学療法が最も広く好まれるがん治療となっています。しかし、欧米では標的治療薬やバイオシミラーの採用が拡大しており、市場の成長を阻害しています。Amgen 社のNeupogenやNeulasta、Johnson & Johnson Services社のProcrit/Eprexといったブロックバスター薬の特許切れも、市場成長を阻害する要因です。さらに、COVID-19の大流行はがん治療に大きな影響を与えています。パンデミックの間、通院、がん検診、手術、治療が大幅に減少しました。

しかし、パンデミックの影響は減少し、2021年第2四半期から多くの地域で状況は正常に戻りつつあります。主要企業は、薬剤患者の期限切れの機会に対処しており、そのため市場でバイオシミラーを発売しています。バイオシミラーの発売は、がん患者の安価な治療へのアクセス拡大を支えています。例えば、2020年6月、ファイザー社はNeulastaのバイオシミラーであるNYVEPRIA（pegfilgrastim-apgf）の米国FDA承認を取得しました。同剤は、骨髄抑制抗がん剤投与中の非骨髄性悪性腫瘍患者における発熱性好中球減少症の発症を抑制します。2019年11月、Novartis AGはペグフィルグラスチムのバイオシミラー版であるZiextenzoのFDA承認を取得し、同製品は2018年に欧州で商品化されました。

がん支持療法治療薬市場レポートハイライト

– G-CSF（顆粒球コロニー刺激因子）セグメントは2022年に最も高いシェアを占めました。これは、がん関連好中球減少症の主要な治療選択肢です。

– 制吐剤セグメントは、Cinvanti、Sustol、Varubiなどの新薬の上市により、予測期間中にプラス成長が見込まれます。

– 北米およびその他の先進地域市場は予測期間中に縮小が予測されます。

– 先進国市場での売上減少は、複数のバイオシミラーの上市と急速な普及、オピオイド処方の制限に起因すると考えられます。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Definitions
1.1.1.1 Therapeutic Class
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Therapeutic Class Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Cancer Supportive Care Drugs Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration And Growth Prospect Mapping
3.3 Industry Value Chain Analysis
3.4 Supply Demand Analysis
3.5 Market Dynamics
3.5.1 Market Driver Analysis
3.5.1.1 Growing Cancer Prevalence And Increase In Number Of People Receiving Chemotherapy
3.5.1.2 Large Number Of Side Effects Associated With The Cancer Treatment
3.5.2 Market Restraint Analysis
3.5.2.1 Rising Popularity Of Targeted Therapies For The Treatment Of Cancer In Developed Countries
3.5.2.1 Safety Issues Associated With Supportive Care Agents
3.5.3 Industry Opportunity Analysis
3.5.3.1 Development Of Safer Alternatives For Erythropoiesis-Stimulating Agents And Pain Management Products And Launch Of Biosimilars
3.5.4 Industry Challenges
3.5.4.1 Less Developed Cancer Supportive Cancer Market In Low- And Middle-Income Countries (Lmics)
3.6 Cancer Supportive Care Drugs Market Analysis Tools
3.6.1 Industry Analysis – Porter’s
3.6.2 Pestle Analysis
Chapter 4 Cancer Supportive Care Drugs Market – Segment Analysis, By Therapeutic Class, 2018 – 2030 (USD Million)
4.1 Cancer Supportive Care Drugs Market: Therapeutic Class Movement Analysis
4.2 Cancer Supportive Care Drugs Market: Therapeutic Class Estimates And Forecasts, (USD Million)
4.3 G-Csfs(Granulocyte-Colony Stimulating Factors)
4.3.1 G-Csfs (Granulocyte-Colony Stimulating Factors) Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.4 Esas (Erythropoiesis Stimulating Agents)
4.4.1 Esas (Erythropoiesis Stimulating Agents) Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.5 Antiemetics
4.5.1 Antiemetics Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.6 Bisphosphonates
4.6.1 Bisphosphonates Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.7 Opioids
4.7.1 Opioids Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.8 Nsaids And Others
4.8.1 Nsaids And Others Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 5 Cancer Supportive Care Drugs Market – Segment Analysis, By Region, 2018 – 2030 (USD Million)
5.1 Cancer Supportive Care Drugs: Regional Outlook
5.1.1 North America
5.1.1.1 North America Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.1.2 U.S.
5.1.1.2.1 U.S. Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.1.2.2 Key Country Dynamics
5.1.1.2.3 Disease Prevalence
5.1.1.2.4 Regulatory Framework
5.1.1.2.5 Competitive Scenario
5.1.1.3 Canada
5.1.1.3.1 Canada Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.1.3.2 Key Country Dynamics
5.1.1.3.3 Disease Prevalence
5.1.1.3.4 Regulatory Framework
5.1.1.3.5 Competitive Scenario
5.1.2 Europe
5.1.2.1 Europe Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.2.2 Uk
5.1.2.2.1 Uk Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.2.2.2 Key Country Dynamics
5.1.2.2.3 Disease Prevalence
5.1.2.2.4 Regulatory Framework
5.1.2.2.5 Competitive Scenario
5.1.2.3 Germany
5.1.2.3.1 Germany Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.2.3.2 Key Country Dynamics
5.1.2.3.3 Disease Prevalence
5.1.2.3.4 Regulatory Framework
5.1.2.3.5 Competitive Scenario
5.1.2.4 France
5.1.2.4.1 France Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.2.4.2 Key Country Dynamics
5.1.2.4.3 Disease Prevalence
5.1.2.4.4 Regulatory Framework
5.1.2.4.5 Competitive Scenario
5.1.2.5 Italy
5.1.2.5.1 Italy Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.2.5.2 Key Country Dynamics
5.1.2.5.3 Disease Prevalence
5.1.2.5.4 Regulatory Framework
5.1.2.5.5 Competitive Scenario
5.1.2.6 Spain
5.1.2.6.1 Spain Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.2.6.2 Key Country Dynamics
5.1.2.6.3 Disease Prevalence
5.1.2.6.4 Regulatory Framework
5.1.2.6.5 Competitive Scenario
5.1.2.7 Denmark
5.1.2.7.1 Denmark Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.2.7.2 Key Country Dynamics
5.1.2.7.3 Disease Prevalence
5.1.2.7.4 Regulatory Framework
5.1.2.7.5 Competitive Scenario
5.1.2.8 Sweden
5.1.2.8.1 Sweden Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.2.8.2 Key Country Dynamics
5.1.2.8.3 Disease Prevalence
5.1.2.8.4 Regulatory Framework
5.1.2.8.5 Competitive Scenario
5.1.2.9 Norway
5.1.2.9.1 Norway Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.2.9.2 Key Country Dynamics
5.1.2.9.3 Disease Prevalence
5.1.2.9.4 Regulatory Framework
5.1.2.9.5 Competitive Scenario
5.1.3 Asia Pacific
5.1.3.1 Asia Pacific Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.3.2 Japan
5.1.3.2.1 Japan Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.3.2.2 Key Country Dynamics
5.1.3.2.3 Disease Prevalence
5.1.3.2.4 Regulatory Framework
5.1.3.2.5 Competitive Scenario
5.1.3.3 China
5.1.3.3.1 China Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.3.3.2 Key Country Dynamics
5.1.3.3.3 Disease Prevalence
5.1.3.3.4 Regulatory Framework
5.1.3.3.5 Competitive Scenario
5.1.3.4 India
5.1.3.4.1 India Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.3.4.2 Key Country Dynamics
5.1.3.4.3 Disease Prevalence
5.1.3.4.4 Regulatory Framework
5.1.3.4.5 Competitive Scenario
5.1.3.5 South Korea
5.1.3.5.1 South Korea Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.3.5.2 Key Country Dynamics
5.1.3.5.3 Disease Prevalence
5.1.3.5.4 Regulatory Framework
5.1.3.5.5 Competitive Scenario
5.1.3.6 Australia
5.1.3.6.1 Australia Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.3.6.2 Key Country Dynamics
5.1.3.6.3 Disease Prevalence
5.1.3.6.4 Regulatory Framework
5.1.3.6.5 Competitive Scenario
5.1.3.7 Thailand
5.1.3.7.1 Thailand Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.3.7.2 Key Country Dynamics
5.1.3.7.3 Disease Prevalence
5.1.3.7.4 Regulatory Framework
5.1.3.7.5 Competitive Scenario
5.1.4 Latin America
5.1.4.1 Latin America Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.4.2 Brazil
5.1.4.2.1 Brazil Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.4.2.2 Key Country Dynamics
5.1.4.2.3 Disease Prevalence
5.1.4.2.4 Regulatory Framework
5.1.4.2.5 Competitive Scenario
5.1.4.3 Mexico
5.1.4.3.1 Mexico Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.4.3.2 Key Country Dynamics
5.1.4.3.3 Disease Prevalence
5.1.4.3.4 Regulatory Framework
5.1.4.3.5 Competitive Scenario
5.1.4.4 Argentina
5.1.4.4.1 Argentina Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.4.4.2 Key Country Dynamics
5.1.4.4.3 Disease Prevalence
5.1.4.4.4 Regulatory Framework
5.1.4.4.5 Competitive Scenario
5.1.5 MEA
5.1.5.1 MEA Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.5.2 South Africa
5.1.5.2.1 South Africa Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.5.2.2 Key Country Dynamics
5.1.5.2.3 Disease Prevalence
5.1.5.2.4 Regulatory Framework
5.1.5.2.5 Competitive Scenario
5.1.5.3 Saudi Arabia
5.1.5.3.1 Saudi Arabia Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.5.3.2 Key Country Dynamics
5.1.5.3.3 Disease Prevalence
5.1.5.3.4 Regulatory Framework
5.1.5.3.5 Competitive Scenario
5.1.5.4 UAE
5.1.5.4.1 UAE Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.5.4.2 Key Country Dynamics
5.1.5.4.3 Disease Prevalence
5.1.5.4.4 Regulatory Framework
5.1.5.4.5 Competitive Scenario
5.1.5.5 Kuwait
5.1.5.5.1 Kuwait Cancer Supportive Care Drugs Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.1.5.5.2 Key Country Dynamics
5.1.5.5.3 Disease Prevalence
5.1.5.5.4 Regulatory Framework
5.1.5.5.5 Competitive Scenario
Chapter 6 Competitive Landscape
6.1 Company Categorization
6.1.1 Strategy Mapping
6.1.2 New Product Launch
6.1.3 Partnerships
6.1.4 Acquisition
6.1.5 Collaboration
6.2 Company Market Share Analysis, 2022
6.3 Company Profiles
6.3.1 Amgen, Inc.
6.3.1.1 Company Overview
6.3.1.2 Financial Performance
6.3.1.3 Product Benchmarking
6.3.1.4 Strategic Initiatives
6.3.2 Merck & Co., Inc.
6.3.2.1 Company Overview
6.3.2.2 Financial Performance
6.3.2.3 Product Benchmarking
6.3.2.4 Strategic Initiatives
6.3.3 Johnson & Johnson Services, Inc.
6.3.3.1 Company Overview
6.3.3.2 Financial Performance
6.3.3.3 Product Benchmarking
6.3.3.4 Strategic Initiatives
6.3.4 Heron Therapeutics, Inc.
6.3.4.1 Company Overview
6.3.4.2 Financial Performance
6.3.4.3 Product Benchmarking
6.3.4.4 Strategic Initiatives
6.3.5 Novartis Ag
6.3.5.1 Company Overview
6.3.5.2 Financial Performance
6.3.5.3 Product Benchmarking
6.3.5.4 Strategic Initiatives
6.3.6 Gsk Plc
6.3.3.1 Company Overview
6.3.3.2 Financial Performance
6.6.3.3 Product Benchmarking
6.6.3.4 Strategic Initiatives
6.3.7 F. Hoffmann-La Roche Ltd.
6.3.7.1 Company Overview
6.3.7.2 Financial Performance
6.3.7.3 Product Benchmarking
6.3.7.4 Strategic Initiatives
6.3.8 Helsinn Healthcare Sa
6.3.8.1 Company Overview
6.3.8.2 Financial Performance
6.3.8.3 Product Benchmarking
6.3.8.4 Strategic Initiatives

List of Tables

TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Regulatory Framework
TABLE 4 Global Cancer Supportive Care Drugs Market, By Region, 2018 - 2030 (USD Million)
TABLE 5 Global Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 6 North America Cancer Supportive Care Drugs Market, By Country, 2018 - 2030 (USD Million)
TABLE 7 North America Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 8 U.S. Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 9 Canada Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 10 Europe Cancer Supportive Care Drugs Market, By Country, 2018 - 2030 (USD Million)
TABLE 11 Europe Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 12 UK Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 13 Germany Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 14 France Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 15 Italy Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 16 Spain Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 17 Denmark Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 18 Sweden Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 19 Norway Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 20 Asia Pacific Cancer Supportive Care Drugs Market, By Country, 2018 - 2030 (USD Million)
TABLE 21 Asia Pacific Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 22 Japan Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 23 China Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 24 India Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 25 South Korea Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 26 Australia Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 27 Thailand Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 28 Latin America Cancer Supportive Care Drugs Market, By Country, 2018 - 2030 (USD Million)
TABLE 29 Latin America Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 30 Brazil Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 31 Mexico Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 32 Argentina Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 33 MEA Cancer Supportive Care Drugs Market, By Country, 2018 - 2030 (USD Million)
TABLE 34 MEA Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 35 South Africa Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 36 Saudi Arabia Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 37 UAE Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)
TABLE 38 Kuwait Cancer Supportive Care Drugs Market, By Therapeutic Class, 2018 - 2030 (USD Million)

★調査レポート[世界のがん支持療法治療薬市場2023-2030：治療薬クラス別（G-CSF、ESA、制吐薬、ビスホスホネート、オピオイド、NSAID）、地域別（北米、ヨーロッパ）] (コード：GRV23JUN004)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のがん支持療法治療薬市場2023-2030：治療薬クラス別（G-CSF、ESA、制吐薬、ビスホスホネート、オピオイド、NSAID）、地域別（北米、ヨーロッパ）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のがん支持療法薬市場2023-2030：種類別（ESA、G-CSF、制吐剤、ビスフォスフォネート、オピオイド、その他）、用途別（乳がん、肺がん、大腸がん、前立腺がん、肝がん、その他）、流通チャネル別（病院薬局、ドラッグストア＆小売薬局、オンラインプロバイダー）、地域別
  • 世界の閉経後骨粗鬆症治療市場2023-2030：薬剤種類別（ビスホスホネート、ビタミンD3）、流通チャネル別（小売薬局、病院薬局）
  • 世界のロボット支援内視鏡市場（2023-2030）：用途別（病院、外来施設）、地域別（北米、アジア太平洋、ヨーロッパ、中南米、中東・アフリカ）
  • 世界のデュピュイトラン病市場2023-2030：種類別（診断、治療）、疾患種類別（タイプ I、タイプ II）、最終用途別（病院、診療所）、地域別（ヨーロッパ、アジア太平洋）
  • 世界のコンシューマーゲノミクス市場2024-2030：用途別（遺伝子関連、家系、診断、スポーツ栄養＆健康）、地域別（北米、ヨーロッパ）
  • 世界の加湿器市場2023-2030：製品別（加熱式加湿器、内蔵式加湿器）、最終用途別（病院、外来施設）、地域別（ヨーロッパ、北米）

    • ◆H&Iグローバルリサーチのお客様（例）◆